Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,657 across all filing types
Latest filing 2021-03-29 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
2020年度独立董事述职报告（何素英）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2020" from Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the independent director's attendance at board and shareholder meetings, opinions on various company matters, participation in committees, supervision of internal controls and information disclosure, and other duties performed during the year 2020. The content is a detailed report on the independent director's activities and responsibilities over the year, rather than an announcement or a brief summary. It does not contain financial statements or audit results but focuses on governance and director duties. This fits the category of Board/Management Information (MANG), which includes announcements or reports related to board members and senior management activities. The document length is 3440 characters, which is relatively short but contains substantive content about the independent director's work rather than just an announcement of a report publication. Therefore, the best classification is MANG with high confidence.
2021-03-29 Chinese
关于拟续聘2021年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the proposed reappointment of the audit firm for the fiscal year 2021. It details the qualifications, independence, and past performance of the audit firm, as well as the approval process by the board and audit committee. The document does not contain an actual audit report or financial statements but rather discusses the appointment of the auditor and related procedural matters. The document length is 4112 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document fits the category of an Audit Report / Information announcement about the auditor appointment rather than the audit report itself. FY 2021
2021-03-29 Chinese
关于2020年度拟不进行利润分配的专项说明
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an official announcement from Shenzhen Xintai Pharmaceutical Co., Ltd. regarding the company's 2020 profit distribution plan, specifically stating that no cash dividends will be distributed and that undistributed profits will be carried forward. It includes details about the company's net profit, legal reserves, share repurchases treated as dividends, and the rationale behind the decision. The document also contains opinions from independent directors and the supervisory board, and mentions that the plan will be submitted to the 2020 annual shareholders' meeting for approval. The document is relatively short (4183 characters) and primarily serves as a formal announcement of the profit distribution plan rather than a full financial report or annual report. It does not contain comprehensive financial statements or detailed financial analysis. Therefore, it fits best into the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it relates to shareholder decisions on profit distribution to be voted on at the annual meeting.
2021-03-29 Chinese
第五届监事会第十一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Shenzhen Salubris Pharmaceuticals Co., Ltd. It discusses the approval of the 2020 Supervisory Board Work Report, the 2020 Annual Report and its summary, the 2020 profit distribution plan, internal control self-evaluation report, accounting policy changes, and the use of idle funds for financial products. The document states that the 2020 Annual Report and related reports will be submitted to the 2020 Annual General Meeting for approval. The document itself does not contain the full annual report or detailed financial statements but rather announces the resolutions and approvals made by the Supervisory Board. The document length is 3261 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, according to the MENU VS MEAL RULE, this document is an announcement of resolutions related to the annual report and other supervisory matters, not the annual report itself. The best fitting category is Regulatory Filings (RNS), as it is a regulatory announcement of supervisory board resolutions and approvals related to the annual report and other corporate governance matters.
2021-03-29 Chinese
关于非公开发行股票申请获得中国证监会核准批复的公告
Capital/Financing Update Classification · 100% confidence The document is an announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the approval from the China Securities Regulatory Commission (CSRC) for a non-public issuance of shares. It details the approval, conditions, and contact information related to the issuance. There is no financial data or report content, only an official notice about the capital raising activity. This fits the category of Capital/Financing Update (CAP). The document length is short and focused on the financing event, not a full report or regulatory filing.
2021-03-09 Chinese
关于高级管理人员辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a senior management personnel (the company's vice general manager). It includes details about the resignation, its effective date, and confirms no outstanding commitments or shareholdings by the resigning executive. There is no financial data, no mention of a report or meeting, and it clearly relates to management changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on management change, confirming this classification with high confidence.
2021-03-02 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.